KEGG DRUG: Casirivimab (original) (raw)
| 
| | DRUG: Casirivimab |
| ------------------------------------------------------------- | | ----------------- |
| Entry | D11938 Drug |
|---|---|
| Name | Casirivimab (USAN);Casirivimab (genetical recombination) (JAN) |
| Formula | C6454H9976N1704O2024S44 |
| Exact mass | 145143.7789 |
| Mol weight | 145233.41 |
| Sequence | (Heavy chain)QVQLVESGGG LVKPGGSLRL SCAASGFTFS DYYMSWIRQA PGKGLEWVSY ITYSGSTIYYADSVKGRFTI SRDNAKSSLY LQMNSLRAED TAVYYCARDR GTTMVPFDYW GQGTLVTVSSASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSSGLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGGPSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYNSTYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDELTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRWQQGNVFSCSV MHEALHNHYT QKSLSLSPGK(Light chain)DIQMTQSPSS LSASVGDRVT ITCQASQDIT NYLNWYQQKP GKAPKLLIYA ASNLETGVPSRFSGSGSGTD FTFTISGLQP EDIATYYCQQ YDNLPLTFGG GTKVEIKRTV AAPSVFIFPPSDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLTLSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC(Disulfide bridge: H22-H96, H147-H203, H223-L214, H229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'147-H'203, H'223-L'214, H'264-H'324, H'370-H'428, L23-L88, L134-L194, L'23-L'88, L'134-L'194) |
| Type | Peptide |
| Class | Antiviral DG03174 Anti-SARS-CoV-2 agent |
| Remark | Product (mixture): D12142<JP> |
| Efficacy | Antiviral |
| Type | Monoclonal antibody |
| Comment | Treatment and prophylaxis of SARS-CoV-2 infection (COVID-19) |
| Target | SARS-CoV-2 spike glycoprotein [KO:K24152] |
| Pathway | ko03230 Viral genome structureko05171 Coronavirus disease - COVID-19 |
| Brite | Drug groups [BR:br08330] Antiviral DG03174 Anti-SARS-CoV-2 agent D11938 CasirivimabAntimicrobials [BR:br08307] Antivirals Entry, fusion or uncoating inhibitor Coronavirus spike protein D11938 Casirivimab (USAN) |
| Other DBs | CAS: 2415933-42-3PubChem: 497620351 |
| LinkDB |